CONMED Corporation 2013 Q3 Form 10-Q Summary
Business Context and Reporting Period
CONMED is a medical technology company focused on surgical devices and equipment for minimally invasive procedures and monitoring. The filing covers the unaudited three and nine months ended September 30, 2013, compared with the corresponding 2012 periods. Effective January 1, 2013, CONMED reports as a single global operating segment. International sales represented approximately 50.3% of third-quarter sales and 50.9% of year-to-date sales.
Financial Performance and Liquidity
| Metric | Q3 2013 | Q3 2012 | 9M 2013 | 9M 2012 |
|---|---|---|---|---|
| Net sales | $179.3 million | $181.9 million | $559.3 million | $565.9 million |
| Gross profit | $95.4 million | $97.9 million | $301.0 million | $298.6 million |
| Gross margin | 53.2% | 53.8% | 53.8% | 52.8% |
| Income from operations | $8.8 million | $14.1 million | $40.3 million | $48.2 million |
| Operating margin | 4.8% | 7.7% | 7.2% | 8.6% |
| Net income | $5.7 million | $9.3 million | $25.7 million | $29.6 million |
| Diluted EPS | $0.20 | $0.32 | $0.91 | $1.03 |
- Third-quarter sales declined 1.4%; year-to-date sales declined 1.2%. Capital equipment sales decreased 11.9% in the quarter, while single-use product sales increased 1.3%.
- Q3 product-line sales were $95.6 million for orthopedic surgery, $69.9 million for general surgery and $13.8 million for surgical visualization. Visualization sales declined 16.4%, primarily from lower video-system sales.
- Year-to-date gross margin improved by 1.0 percentage point due primarily to completed restructuring initiatives, but Q3 gross margin declined because of charges related to discontinuing a patient-monitoring product.
- Year-to-date selling and administrative expense increased to $228.4 million from $222.6 million, while research and development expense decreased to $19.4 million from $21.4 million.
- The 2.3% U.S. medical device excise tax reduced 2013 results by $1.4 million in Q3 and $4.4 million year to date.
- Net cash provided by operating activities was $53.6 million for the first nine months, compared with $61.3 million in 2012. Capital expenditures were $13.6 million, and management expected approximately $20.0 million for full-year 2013.
- Cash and cash equivalents were $49.8 million at September 30, 2013, compared with $23.7 million at December 31, 2012. Net working capital was $263.0 million.
- Total debt was approximately $225.1 million, including $217.0 million outstanding under the revolving credit facility and $8.1 million under a mortgage note. Available revolver capacity was $124.4 million, with approximately $8.6 million reserved for letters of credit. The company was in compliance with its debt covenants.
Material Changes Versus the Prior Comparable Period
- Revenue and profitability weakened in Q3 and during the first nine months, primarily due to lower capital-equipment demand, weaker orthopedic and visualization sales, the medical device excise tax, higher administrative costs and legal expenses.
- Year-to-date gross margin improved despite lower sales, reflecting manufacturing and administrative restructuring benefits. However, selling and administrative expense increased as a percentage of sales.
- The company refinanced its senior credit facility in January 2013 with a $350.0 million revolving facility expiring January 17, 2018. The refinancing generated a $0.3 million loss on early extinguishment of debt.
- CONMED repurchased $44.7 million of common stock during the first nine months and had $60.1 million remaining under its $200.0 million authorization. It paid $12.6 million in dividends.
- CONMED paid $34.0 million in 2013 toward its contingent obligation under the Musculoskeletal Transplant Foundation distribution agreement. A remaining $50.0 million obligation was accrued because the company considered achievement of the applicable supply targets probable.
Guidance, Outlook, Risks and Unusual Items
- Management estimated 2013 restructuring and related costs of approximately $19.0 million to $20.0 million. The restructuring includes facility consolidations, production transfers to Mexico, administrative changes and discontinuation of a patient-monitoring product. A $3.7 million restructuring accrual remained at September 30, 2013.
- Management stated that operating cash flow, cash on hand and available borrowing capacity should be adequate for working capital, debt service, capital expenditures and planned share repurchases in the foreseeable future.
- Key risks include weak economic conditions and customer purchasing patterns, foreign currency and interest-rate volatility, competition, product acceptance, regulatory compliance, supply and quality issues, acquisition integration, allograft tissue availability and litigation.
- Bonutti Skeletal Innovations filed a patent-infringement complaint involving selected CONMED products. The company intends to defend the claims, but a range of potential losses could not be estimated.
- The filing states that pending legal matters are not expected to have a material adverse effect, while noting that future claims, investigations or uninsured costs could materially affect results.
- Management identified no significant changes in market-risk exposures and concluded that disclosure controls and procedures were effective as of September 30, 2013.
Important Facts for Investors to Verify
- Whether revenue declines, particularly in capital equipment and surgical visualization, persist into subsequent periods.
- Whether restructuring initiatives deliver the expected savings and whether the projected $19.0 million to $20.0 million of 2013 costs are accurate.
- The cash-flow effect of the MTF agreement, including the accrued $50.0 million remaining contingent obligation.
- Revolver utilization, covenant compliance, interest-rate exposure and the company’s ability to fund repurchases and dividends while debt remains elevated.
- The potential financial and operational impact of the Bonutti patent litigation and other regulatory or product-liability matters.
- Whether the improved year-to-date gross margin can offset higher selling and administrative costs, the medical device excise tax and continuing sales pressure.